Alachua, FL, October 9, 2013 – AxoGen, Inc. (NASDAQ: AXGN), a leader in the science and commercialization of surgical solutions for peripheral nerve repair, today announced the presentation of data on Avance® Nerve Graft at the American Association of Oral and Maxillofacial Surgeons (AAOMS) 95th Annual Meeting, taking place October 7-12 in Orlando, Florida.
The Avance® Nerve Graft data will be presented by oral and maxillofacial surgery specialists David Yates DMD, MD, and John Zuniga DMD, PhD, both from University of Texas Southwestern Medical Center in Dallas, Texas. The details of the oral poster presentation are as follows:
Presentation Title: Processed Nerve Allograft for Trigeminal Nerve Repair: Safety and Effectiveness in Sensory Nerve Reconstruction
Date/Time: Thursday, October 10, 2013: 8:40 a.m. ET
Location: W414A, Orange County Convention Center, Orlando
Jill Schiaparelli, Senior Vice President, Business Strategy & Marketing at AxoGen, said, “Trigeminal nerve injuries can be caused by common dental procedures such as wisdom tooth removal and dental implants and may result in significant pain and discomfort for affected patients. We are pleased that Drs. Yates and Zuniga will be presenting their experience with Avance® Nerve Graft as a repair option for trigeminal nerve injuries at the AAOMS Annual Meeting.”
AxoGen is exhibiting its full portfolio of nerve repair and protection technologies and products at Booth 1507.
Avance® Nerve Graft is processed nerve allograft (human) intended for the surgical repair of peripheral nerve discontinuities to support regeneration across the defect. The product provides surgeons a readily-available nerve allograft to repair peripheral nerves damaged by trauma or resected during a surgical procedure.
About AxoGen, Inc.
AxoGen (NASDAQ: AXGN) is a leading regenerative medicine company dedicated to advancing the science and commercialization of peripheral nerve repair solutions. The Company’s innovative approach to regenerative medicine has resulted in first-in-class products that have defined their product categories. AxoGen’s products offer a full suite of surgical nerve repair solutions including Avance® Nerve Graft, the only off-the-shelf commercially available processed nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site, AxoGuard® Nerve Connector, a porcine submucosa ExtraCellular Matrix (ECM) coaptation aid for tensionless repair of severed nerves, and AxoGuard® Nerve Protector, a porcine submucosa ECM product used to wrap and protect injured peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments.
AxoGen is the parent of its wholly owned operating subsidiary, AxoGen Corporation. Avance® Nerve Graft is processed in the United States by AxoGen. AxoGuard® Nerve Connector and AxoGuard® Nerve Protector are manufactured in the United States by Cook Biotech Incorporated, West Lafayette, Indiana, and are distributed exclusively by AxoGen. AxoGen’s principal executive office and operations are located in Alachua, FL. For more information on AxoGen and its technology, please visit www.AxoGenInc.com. To receive email alerts directly from AxoGen, please click here www.axogeninc.com/emailalerts.html.
Cautionary Statements Concerning Forward-Looking Statements
This Press Release contains “forward-looking” statements as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management’s current expectations or predictions of future conditions, events or results based on various assumptions and management’s estimates of trends and economic factors in the markets in which we are active, as well as our business plans. Words such as “expects”, “anticipates”, “intends”, “plans”, “believes”, “seeks”, “estimates”, “projects”, “forecasts”, “continue”, “may”, “should”, “will” variations of such words and similar expressions are intended to identify such forward-looking statements. The forward-looking statements may include, without limitation, statements regarding product commercialization and marketing efforts for its portfolio of peripheral nerve repair products, Avance® Nerve Graft, AxoGuard® Nerve Connector and AxoGuard® Nerve Protector, product development, financial performance, sales growth, product adoption, market awareness of our products, data validation and our ability to maintain the listing of our common stock on a national securities exchange. The forward-looking statements are subject to risks and uncertainties, which may cause results to differ materially from those set forth in the statements. Forward-looking statements in this release should be evaluated together with the many uncertainties that affect AxoGen’s business and its market, particularly those discussed in the risk factors and cautionary statements in AxoGen’s filings with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and actual results may differ materially from those projected. The forward-looking statements are representative only as of the date they are made, and AxoGen assumes no responsibility to update any forward-looking statements, whether as a result of new information, future events or otherwise.
This press release does not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Any offer, if at all, will be made only by means of the registration statement and the final prospectus.
Contact:
AxoGen, Inc.
Greg Freitag, Chief Financial Officer & General Counsel
386.462.6856
InvestorRelations@AxoGenInc.com
Help employers find you! Check out all the jobs and post your resume.
